Genzyme, the biotechnology company with operations in MetroWest, has submitted a new drug application to the U.S. Food and Drug Administration for treatment of a genetic cardiovascular disease.
The drug, mipomersen sodium, was originally developed by Isis Pharmaceutical Inc. of California. FDA acceptance of the application would trigger a $25 million milestone payment from Genzyme to Isis under a 2008 licensing agreement.
Genzyme plans to market the drug to patients with a condition known as homozygous familial hypercholesterolemia under the name KYNAMRO.
Read more
